Skip to content
sellModerate cluster of 310b5-1 plan

John Charles Thomas sold $194k of KRYS

EVP, General Counsel at Krystal Biotech, Inc.. 642 shares at an average of $302.03, traded May 26, 2026, filed May 27, 2026.

Warning score
42
Value
$194k
642 shares
Holdings after
0
-100% from before
From 52-week low
+145%
low $123.36, close $302.68
From 52-week high
-4%
high $316.30, as of May 26, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $194k at market
    +12
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

KRYSOct 12, 2026 · close 332.07
Since filing May 27, 2026: +8.3%SPY +4.2% · excess +4.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0002114900-26-000006, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 26, 2026SOpen-market sale
Common Stock10b5-1
-642$302.03$194k0May 27, 2026

Related signals

Other insiders at Krystal Biotech, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$9.0M
25,000 shares
-2%
33Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$9.0M
25,000 shares
-2%
50Moderate
KRYSsell
Krystal Biotech, Inc.
Dino A Rossi
director
$8.2M
25,000 shares
-33%
15Weak
KRYSsell10b5-1
Krystal Biotech, Inc.
John Charles Thomas
EVP, General Counsel
$347k
1,000 shares
-100%
45Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$7.7M
25,000 shares
-2%
40Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$7.7M
25,000 shares
-2%
45Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$6.6M
25,000 shares
-2%
40Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$6.6M
25,000 shares
-2%
40Moderate
KRYSsell 510b5-1
Krystal Biotech, Inc.
Daniel Janney
director
$3.3M
11,803 shares
-14%
7Weak
KRYSsell 510b5-1
Krystal Biotech, Inc.
Kathryn Romano
Chief Accounting Officer
$201k
750 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

John Charles Thomas sold $194k of KRYS | InsiderTell